Among several advances that have contributed to the decreased mortality from breast cancer observed in the past decade, the routine use of adjuvant endocrine therapies directed at the estrogen-estrogen receptor (ER) pathway is a major contributor [1], [2]. The gene discussed is ESR1; the disease is breast cancer.